MedTrace Logo

GSP as an Novel Indicator for Residual Liver Function in Patients With Fatty Liver

NCT04546022 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2020-09-14

No results posted yet for this study

Summary

The primary objective is to determine the galactose single point (GSP) cutoff values to discriminate subjects with different hepatic function. The secondary objective is to analyze the correlations between GSP and other hepatic function assessment methods among this trial subjects.

Conditions

  • Galactose Single Point (GSP), Residual Liver Function

Interventions

DRUG

Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.

Sponsors & Collaborators

  • Cardinal Tien Hospital

    collaborator OTHER

  • Tri-Service General Hospital

    collaborator OTHER

  • National Defense Medical Center, Taiwan

    lead OTHER

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-05
Primary Completion
2007-08-12
Completion
2018-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04546022 on ClinicalTrials.gov